ZYME Quote, Financials, Valuation and Earnings

CNS Pharmaceuticals has a net margin of -186.56% compared to Zymeworks's net margin of --. Zymeworks's return on equity of -27.06% beat CNS Pharmaceuticals's return on equity of --.

Zymeworks has a consensus price target of $19.86, signalling upside risk potential of 36.94%. On the other hand CNS Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 342.87%. Given that CNS Pharmaceuticals has higher upside potential than Zymeworks, analysts believe CNS Pharmaceuticals is more attractive than Zymeworks.

Zymeworks has a beta of 1.121, which suggesting that the stock is 12.109% more volatile than S&P 500. In comparison CNS Pharmaceuticals has a beta of 1.067, suggesting its more volatile than the S&P 500 by 6.725%.

Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CNS Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. CNS Pharmaceuticals pays out -- of its earnings as a dividend.

Zymeworks quarterly revenues are $16M, which are larger than CNS Pharmaceuticals quarterly revenues of --. Zymeworks's net income of -$29.9M is lower than CNS Pharmaceuticals's net income of -$5.6M. Notably, Zymeworks's price-to-earnings ratio is -- while CNS Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 17.46x versus -- for CNS Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ligand Pharmaceuticals has a net margin of -186.56% compared to Zymeworks's net margin of -13.84%. Zymeworks's return on equity of -27.06% beat Ligand Pharmaceuticals's return on equity of 5.97%.

Zymeworks has a consensus price target of $19.86, signalling upside risk potential of 36.94%. On the other hand Ligand Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 31.88%. Given that Zymeworks has higher upside potential than Ligand Pharmaceuticals, analysts believe Zymeworks is more attractive than Ligand Pharmaceuticals.

Zymeworks has a beta of 1.121, which suggesting that the stock is 12.109% more volatile than S&P 500. In comparison Ligand Pharmaceuticals has a beta of 1.038, suggesting its more volatile than the S&P 500 by 3.81%.

Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. Ligand Pharmaceuticals pays out -- of its earnings as a dividend.

Zymeworks quarterly revenues are $16M, which are smaller than Ligand Pharmaceuticals quarterly revenues of $51.8M. Zymeworks's net income of -$29.9M is lower than Ligand Pharmaceuticals's net income of -$7.2M. Notably, Zymeworks's price-to-earnings ratio is -- while Ligand Pharmaceuticals's PE ratio is 43.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 17.46x versus 12.94x for Ligand Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -186.56% compared to Zymeworks's net margin of 25.23%. Zymeworks's return on equity of -27.06% beat Pfizer's return on equity of 4.63%.

Zymeworks has a consensus price target of $19.86, signalling upside risk potential of 36.94%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.7%. Given that Zymeworks has higher upside potential than Pfizer, analysts believe Zymeworks is more attractive than Pfizer.

Zymeworks has a beta of 1.121, which suggesting that the stock is 12.109% more volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.31% to investors and pays a quarterly dividend of $0.42 per share. Zymeworks pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Zymeworks quarterly revenues are $16M, which are smaller than Pfizer quarterly revenues of $17.7B. Zymeworks's net income of -$29.9M is lower than Pfizer's net income of $4.5B. Notably, Zymeworks's price-to-earnings ratio is -- while Pfizer's PE ratio is 35.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 17.46x versus 2.55x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Revance Therapeutics has a net margin of -186.56% compared to Zymeworks's net margin of -63.65%. Zymeworks's return on equity of -27.06% beat Revance Therapeutics's return on equity of --.

Zymeworks has a consensus price target of $19.86, signalling upside risk potential of 36.94%. On the other hand Revance Therapeutics has an analysts' consensus of $7.64 which suggests that it could grow by 149.58%. Given that Revance Therapeutics has higher upside potential than Zymeworks, analysts believe Revance Therapeutics is more attractive than Zymeworks.

Zymeworks has a beta of 1.121, which suggesting that the stock is 12.109% more volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.478%.

Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend.

Zymeworks quarterly revenues are $16M, which are smaller than Revance Therapeutics quarterly revenues of $59.9M. Zymeworks's net income of -$29.9M is higher than Revance Therapeutics's net income of -$38.1M. Notably, Zymeworks's price-to-earnings ratio is -- while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 17.46x versus 1.15x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.